https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2023-06-29 13:17:002023-06-29 13:18:06Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
Jaclyn Jaffe
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
Jaclyn Jaffe2022-12-14 13:10:452022-12-14 13:17:40Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2022-10-03 17:44:012022-11-14 17:54:30Urica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2022-05-31 16:32:212022-12-01 22:12:22Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating dotinurad for the Treatment of Gout in the United States
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
0
0
admin
https://uricatherapeutics.com/wp-content/uploads/2023/04/logo-new2.png
admin2021-05-10 17:44:152022-12-01 22:13:44Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop dotinurad in North America and Europe
Scroll to top
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
Press ReleasesUrica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa
Press ReleasesUrica Therapeutics Appoints Seasoned Biotech Executive Jay D. Kranzler, M.D., Ph.D., as Chairman and Chief Executive Officer
Press ReleasesFortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating dotinurad for the Treatment of Gout in the United States
Press ReleasesFortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop dotinurad in North America and Europe
Press Releases